FDA advisory panel on Wednesday votes in favor of Gilead's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.
Eric Risberg / AP fileAn FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.
The treatment, Descovy, is a combination of emtricitabine and tenofovir alafenamide, and is already approved to treat chronic HIV. When asked to assess the efficacy of Descovy for pre-exposure prophylaxis of HIV in men and transgender women who have sex with men, a patient population that forms the largest component of the PrEP market, the panel voted 16-2 in favor.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA panel backs Gilead's HIV prevention drug Descovy, except in womenAn FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's ...
Consulte Mais informação »
Patient groups push back against Gilead's pricey HIV prevention treatmentGilead Sciences Inc hopes to soon introduce a pricey new pill to prevent HIV in ...
Consulte Mais informação »
FDA Says Data Manipulated for Novartis Gene Therapy DrugThe Food and Drug Administration said “data manipulation” took place during the clinical trial of Zolgensma, the world’s most expensive drug, but officials said the gene therapy product still should stay on the market.
Consulte Mais informação »
FDA raises accuracy questions over trial data of $2 million gene therapy drugMore than 2 months after the FDA approved an expensive new gene therapy drug for a rare disease in children, the agency said it has major questions about the accuracy of some of the testing data.
Consulte Mais informação »
FDA investigating 127 reports of seizures after vapingThe FDA cautions it's unclear whether e-cigarettes caused the seizures.
Consulte Mais informação »
FDA: Pricey Drug Approved on Manipulated DataApproval for a drug meant to treat children with a severe form of spinal muscular atrophy -- which costs over $2 million for a single treatment -- was based on manipulated data provided by the drug's maker, the FDA reports.
Consulte Mais informação »